Ectopic Pregnancy

1. Clinical Overview

Summary

An ectopic pregnancy is the implantation of a fertilized ovum outside the normal uterine endometrial cavity. Over 95% of ectopic pregnancies occur in the Fallopian tube, with the ampulla being the most common site. Ectopic pregnancy remains a leading cause of maternal morbidity and mortality in the first trimester, accounting for 6-13% of all pregnancy-related deaths in developed countries. [1,2]

The incidence has increased significantly over recent decades, rising from 4.5 per 1000 pregnancies in 1970 to approximately 20 per 1000 pregnancies currently, largely attributed to increased rates of pelvic inflammatory disease, assisted reproductive technology, and improved diagnostic capabilities. [3] However, mortality has decreased dramatically due to early diagnosis via transvaginal ultrasound (TVUSS) and serial serum β-hCG monitoring, shifting management from emergency laparotomy to conservative medical and minimally invasive surgical options. [4]

Early recognition is critical: the classic triad of amenorrhoea, abdominal pain, and vaginal bleeding occurs in only 45-50% of cases. A high index of suspicion and routine pregnancy testing in any woman of reproductive age presenting with abdominal pain or collapse is essential for timely diagnosis. [5]

Key Anatomical Sites

Tubal Ectopic (95-97%):

• Ampulla (65-70%): Most common site. The widest portion of the tube allows the pregnancy to develop longer before rupture, typically presenting at 6-10 weeks gestation.
• Isthmus (10-15%): The narrowest portion of the tube. Limited capacity for distension results in earlier rupture (typically 6-8 weeks) and higher risk of catastrophic haemorrhage.
• Fimbrial (5-10%): Implantation at the distal end. May result in "tubal abortion" where the pregnancy spontaneously detaches and is expelled into the peritoneal cavity.
• Interstitial/Cornual (2-4%): Implantation within the muscular portion of the tube as it traverses the uterine wall. The rich myometrial blood supply allows growth to 10-16 weeks before rupture, leading to catastrophic haemorrhage with maternal mortality up to 2.5%. [6,7]

Non-Tubal Ectopic (3-5%):

• Cervical (less than 1%): Implantation in the cervical canal. High risk of massive haemorrhage during intervention.
• Ovarian (1-3%): Primary implantation on the ovary surface or within an ovarian follicle.
• Abdominal (less than 1%): Primary peritoneal implantation or secondary implantation following tubal abortion.
• Caesarean Scar (increasing incidence, 0.15% of pregnancies with prior CS): Implantation in the myometrial defect of a previous caesarean section scar. Risk of uterine rupture and massive haemorrhage. [8]

Clinical Pearls

The "Classic Triad" is Unreliable: Only 45-50% of patients present with the classic triad of (1) amenorrhoea, (2) abdominal pain, and (3) vaginal bleeding. Up to 20% of patients with ruptured ectopic pregnancy deny a missed period, as early bleeding may be mistaken for menstruation. Always perform a urine pregnancy test in ANY woman of reproductive age (typically 15-45 years) presenting with abdominal pain, collapse, or unexplained shock, regardless of menstrual history. [5,9]

Diarrhoea and Dizziness - The Subtle Presentation: Haemoperitoneum causes blood to collect in the Pouch of Douglas (rectouterine pouch), the most dependent part of the peritoneal cavity. This irritates the rectum causing loose stools, tenesmus, or rectal pressure. Simultaneously, peritoneal blood triggers vagal stimulation causing vasovagal symptoms including dizziness, presyncope, or frank syncope. The combination of gastrointestinal symptoms with vasovagal features in early pregnancy is highly suggestive of ruptured ectopic pregnancy. [10]

Heterotopic Pregnancy: The simultaneous occurrence of intrauterine and ectopic pregnancy. In spontaneous conception, the incidence is rare (1:30,000 pregnancies). However, with assisted reproductive technology (ART), particularly when multiple embryos are transferred, the risk increases dramatically to 1:100-1:500 pregnancies. Visualization of an intrauterine pregnancy does NOT exclude ectopic pregnancy in patients who have undergone IVF. [11,12]

Shoulder Tip Pain Mechanism: Referred pain to the shoulder tip (C3-C5 dermatome) occurs via phrenic nerve irritation from blood tracking along the paracolic gutters to accumulate beneath the diaphragm. This is a highly specific sign of haemoperitoneum and mandates urgent surgical evaluation. [13]

---

2. Epidemiology

Incidence and Prevalence

• Global Incidence: 1-2% of all pregnancies in developed countries. Rates vary geographically, with higher incidence in developing nations due to increased prevalence of pelvic inflammatory disease. [3]
• Temporal Trends: Incidence has increased 4-fold over the past 40 years (from ~5 per 1000 to ~20 per 1000 pregnancies), while mortality has decreased by over 90% due to earlier diagnosis. [4]
• Age Distribution: Peak incidence occurs in women aged 35-44 years. Adolescents (under 18) have a 3-fold higher risk of mortality from ectopic pregnancy compared to women in their 20s. [14]
• Recurrence Rate: 10-15% after one ectopic pregnancy; increases to 25-30% after two consecutive ectopic pregnancies. [15]

Risk Factors

High-Risk Factors (Odds Ratio 5-20):

1. Previous Ectopic Pregnancy: OR 10-15. The single strongest risk factor. [15]
2. Previous Tubal Surgery: Salpingostomy, tubal sterilization, tubal reanastomosis. OR 20-50. [16]
3. Documented Tubal Pathology: Hydrosalpinx, tubal adhesions. OR 12-25. [17]
4. In Utero Diethylstilbestrol (DES) Exposure: Congenital tubal abnormalities. OR 5-10. (Historical risk factor). [18]

Moderate-Risk Factors (Odds Ratio 2-5):

1. Pelvic Inflammatory Disease (PID): OR 3-4. Chlamydia trachomatis is the most common causative organism, responsible for 30-50% of PID cases leading to tubal damage. Silent or subclinical infection is common, with many women having no prior diagnosis of PID. [19,20]
2. Assisted Reproductive Technology (ART): OR 2-3. Risk varies by technique - ovulation induction (OR 2), intrauterine insemination (OR 1.5-2), IVF/ICSI (OR 1.5-3). Embryo transfer to a damaged or dysfunctional tube contributes to risk. [21]
3. Current Use of Intrauterine Contraceptive Device (IUCD): IUCDs are highly effective at preventing intrauterine pregnancy (99%+) but less effective at preventing tubal pregnancy. If pregnancy occurs in a woman with an IUCD in situ, there is a 15-50% chance it is ectopic. The absolute risk remains low given the overall efficacy of IUCDs. [22]
4. Progestogen-Only Contraceptive Failure: Progestogen-only pills (POP) and progestogen implants/injections slow tubal motility. If contraceptive failure occurs, relative risk of ectopic is increased (OR 2-3). [23]
5. Cigarette Smoking: Current smokers have OR 1.5-3 in a dose-dependent manner. Nicotine impairs tubal ciliary function and smooth muscle contractility. The mechanism involves altered PROKR1 (prokineticin receptor 1) expression in the Fallopian tube. [24,25]

Low-Risk Factors (Odds Ratio 1.5-2):

1. Previous Pelvic/Abdominal Surgery: Non-tubal surgery including appendicectomy, caesarean section, ovarian cystectomy. OR 1.5-2. [16]
2. Endometriosis: Pelvic adhesions and tubal dysfunction. OR 1.7. [26]
3. Multiple Sexual Partners / Early Age at First Intercourse: Surrogate markers for STI exposure. OR 1.5-2. [20]
4. Infertility (unrelated to tubal factors): OR 1.5-2. May reflect underlying ovulatory dysfunction or altered tubal environment. [21]
5. Previous Caesarean Section: Risk of caesarean scar ectopic specifically. OR 1.5-2 for subsequent pregnancies. [8]

Protective Factors:

• Previous Live Birth: OR 0.5-0.7 (protective).
• Barrier Contraception: Condoms reduce STI transmission and thus PID risk.
• Combined Oral Contraceptive Pill (COCP): Reduces PID risk through cervical mucus thickening. [27]

---

3. Pathophysiology

Normal Tubal Transport

Following fertilization in the ampulla of the Fallopian tube, the embryo undergoes cell division while being transported toward the uterine cavity over 3-4 days. Tubal transport depends on:

1. Ciliary Beat: Coordinated beating of ciliated epithelial cells propels the embryo distally.
2. Smooth Muscle Peristalsis: Coordinated tubal contractions.
3. Tubal Fluid Flow: Secreted by non-ciliated secretory cells.

The embryo typically enters the uterine cavity at the morula or early blastocyst stage (day 4-5 post-fertilization) and implants in the endometrium around day 6-7. [28]

Mechanism of Ectopic Implantation

Ectopic pregnancy occurs when embryo transport is delayed or arrested, allowing the blastocyst to reach implantation competency while still within the tube. Key mechanisms include:

1. Structural Tubal Damage:

   • Post-Infectious Adhesions: PID causes tubal mucosal damage, loss of ciliated cells, intraluminal adhesions, and diverticula formation. Chlamydial heat-shock protein 60 (cHSP60) triggers an inflammatory cascade leading to scarring. [19,29]
   • Surgical Scarring: Previous tubal surgery creates strictures, adhesions, or diverticula that impede embryo passage.

2. Functional Tubal Dysfunction:

   • Altered Ciliary Function: Smoking, hormonal imbalance (progestogens), and inflammatory mediators impair ciliary beating and coordination.
   • Abnormal Peristalsis: Altered smooth muscle contractility due to hormonal influences or intrinsic tubal pathology.
   • Reversed Transport: Embryo reflux from the uterus back into the tube (transperitoneal migration) may occur following IVF embryo transfer.

3. Embryo Factors:

   • Premature Implantation Competency: The embryo develops implantation capability before reaching the uterus. This may be influenced by embryo quality and endometrial receptivity factors.

Consequences of Tubal Implantation

Unlike the endometrium, the Fallopian tube lacks a developed decidual layer and has limited capacity for distension. As the trophoblast invades:

1. Tubal Wall Erosion: Trophoblastic tissue invades through the mucosa and muscularis, eroding into tubal blood vessels.

2. Haematoma Formation: Bleeding into the tubal lumen causes tubal distension and haematosalpinx.

3. Tubal Rupture: Progressive distension and vascular erosion lead to rupture through the tubal wall, typically at 6-12 weeks gestation depending on location:

   • Isthmic rupture: Earlier (6-8 weeks) due to narrow lumen.
   • Ampullary rupture: Later (8-12 weeks) due to greater capacity for distension.
   • Interstitial rupture: Latest (10-16 weeks) as the thick myometrium can accommodate more growth. [6,30]

4. Haemoperitoneum: Blood accumulates in the peritoneal cavity, pooling in the Pouch of Douglas and potentially tracking to the subdiaphragmatic spaces. Volume loss can exceed 2-3 litres in cornual rupture.

5. Tubal Abortion: The pregnancy may spontaneously separate and be expelled through the fimbrial end into the peritoneal cavity, sometimes resulting in secondary abdominal implantation.

Molecular Mechanisms

Recent research has identified molecular alterations in ectopic pregnancy:

• Altered PROKR1 Expression: Prokineticin receptor 1, which regulates tubal contractility, shows abnormal expression patterns. [25]
• Leukemia Inhibitory Factor (LIF): Aberrant expression may facilitate ectopic implantation.
• Integrin Expression: Altered αvβ3 integrin expression in tubal epithelium may promote implantation outside the uterus. [31]

---

4. Clinical Presentation

Symptoms

The clinical presentation is highly variable, ranging from asymptomatic (incidental finding on scan) to life-threatening haemorrhagic shock.

Common Symptoms:

1. Abdominal Pain (90-100%):

   • Typically unilateral lower abdominal or pelvic pain, corresponding to the affected side.
   • Character varies: Sharp, cramping, or dull/aching.
   • May be initially intermittent, becoming constant as tubal distension progresses.
   • Sudden-onset severe generalized abdominal pain suggests rupture with haemoperitoneum.

2. Vaginal Bleeding (50-80%):

   • Typically light "spotting," often described as dark brown ("prune juice") due to old blood.
   • Usually less than a normal menstrual period.
   • Absence of bleeding does NOT exclude ectopic pregnancy.

3. Amenorrhoea (75-95%):

   • Most patients report a missed period (6-10 weeks amenorrhoea typical).
   • 10-15% report "normal" last menstrual period - bleeding from decidual shedding or implantation bleeding may be mistaken for menses.

4. Shoulder Tip Pain (10-25%, higher in ruptured ectopic):

   • Referred pain to the C3-C5 dermatome from diaphragmatic irritation by blood.
   • Highly specific for haemoperitoneum - mandates urgent evaluation.
   • May be exacerbated by lying flat or Trendelenburg position.

5. Gastrointestinal Symptoms (20-35%):

   • Rectal pressure, tenesmus, or urge to defecate (blood in Pouch of Douglas).
   • Diarrhoea or loose stools.
   • Nausea and vomiting (may mimic gastroenteritis or appendicitis).

6. Dizziness/Syncope (10-35%, higher in ruptured):

   • Presyncope, near-fainting, or frank syncope.
   • Vasovagal response to peritoneal irritation and/or hypovolaemia.
   • Syncope is a red flag for rupture and haemodynamic compromise.

Asymptomatic Presentation:

• 5-10% of ectopic pregnancies are asymptomatic, discovered incidentally during routine early pregnancy ultrasound. [5,9]

Signs

General Examination:

• Vital Signs:
  • "Tachycardia: Early sign of hypovolaemia. Compensatory mechanism before blood pressure falls."
  • "Hypotension: Late sign indicating decompensated shock (usually indicates blood loss > 1500ml)."
  • "Normal Vital Signs: Do NOT exclude ectopic pregnancy. Young, healthy women can maintain normal BP despite significant blood loss through vasoconstriction."
• Pallor: Suggests acute anaemia from blood loss.
• Diaphoresis: Cold, clammy skin in shock.

Abdominal Examination:

• Tenderness: Unilateral or bilateral lower abdominal tenderness. Generalized tenderness suggests haemoperitoneum.
• Guarding and Rebound Tenderness: Peritonism indicates rupture.
• Abdominal Distension: May be present with significant haemoperitoneum.
• Shoulder Tip Pain Reproduction: Pain on palpation of the shoulder or exacerbated by supine positioning.

Pelvic Examination:

• Speculum Examination:

  • "Cervical os: Closed in ectopic pregnancy (differentiates from incomplete/inevitable miscarriage where os is open)."
  • "Bleeding: Minimal dark blood may be visible at os."

• Bimanual Examination (perform gently to avoid rupturing an unruptured ectopic):

  • "Cervical Excitation/Motion Tenderness: Extreme pain on gently moving the cervix from side to side. Highly sensitive (75-95%) but non-specific sign of pelvic peritoneal irritation (also seen in PID, appendicitis, ovarian torsion)."
  • "Adnexal Mass: Palpable tender mass in 30-50% of cases. May be difficult to distinguish from corpus luteum or ovarian cyst."
  • "Adnexal Tenderness: Present in 75-90% of cases."
  • "Uterine Size: Usually normal or slightly enlarged (less than expected for gestational age). An enlarged uterus may suggest intrauterine pregnancy or heterotopic pregnancy. [5,10,13]"

Important Notes:

• Avoid vigorous bimanual examination in suspected ectopic pregnancy as this may precipitate rupture.
• Absence of abnormal signs does NOT exclude ectopic pregnancy - up to 50% of unruptured ectopic pregnancies have a normal pelvic examination.

---

5. Differential Diagnosis

Ectopic pregnancy must be differentiated from other causes of pain and bleeding in early pregnancy:

---

6. Investigations

Bedside Tests

1. Urine Pregnancy Test (Urine hCG):

   • Sensitivity: Detects hCG at levels as low as 20-25 IU/L.
   • Interpretation: Positive test confirms pregnancy but does NOT distinguish intrauterine from ectopic.
   • False Negatives: Very rare in ectopic pregnancy, but can occur in very early pregnancy (less than 3 weeks from LMP) or following complete tubal abortion with falling hCG levels.
   • Clinical Application: Should be performed in ALL women of reproductive age presenting with abdominal pain, collapse, or vaginal bleeding. [32]

2. Vital Signs Monitoring:

   • Pulse: Tachycardia (HR > 100) is an early sign of hypovolaemia.
   • Blood Pressure: Orthostatic hypotension (drop > 20mmHg systolic or > 10mmHg diastolic on standing) suggests volume depletion.
   • Shock Index (HR/SBP): Value > 0.9 suggests significant haemorrhage.

Laboratory Investigations

1. Serum Beta-hCG (β-hCG):

   • Baseline Level:

     • Provides quantitative measurement to guide ultrasound interpretation.
     • Discriminatory Zone: The hCG level above which an intrauterine gestational sac should be visible on TVUSS. Varies by institution and ultrasound quality:
       • Conservative threshold: 1500-2000 IU/L (widely used).
       • Higher thresholds: Up to 3000 IU/L may reduce false-positive diagnoses in viable intrauterine pregnancies.
     • If hCG > 1500 IU/L and no intrauterine pregnancy is visible on TVUSS, ectopic pregnancy is the most likely diagnosis (also consider very early intrauterine pregnancy or complete miscarriage).

   • Serial hCG (48-Hour Trend):

     • Performed when baseline scan is indeterminate (pregnancy of unknown location).
     • Normal Intrauterine Pregnancy: hCG rises by ≥66% (often doubles) in 48 hours. Minimum expected rise is 53% over 48 hours in 99% of viable pregnancies.
     • Ectopic Pregnancy: Suboptimal rise (typically 0-50% increase) or plateau. However, 15-20% of ectopic pregnancies show "normal" doubling, particularly early in gestation.
     • Failing Pregnancy (Miscarriage): hCG declines by ≥35-50% over 48 hours.

   • Limitations: Serial hCG cannot definitively diagnose ectopic pregnancy - correlation with ultrasound findings is essential. [33,34]

2. Serum Progesterone:

   • Single measurement to assess pregnancy viability.
   • Interpretation:
     • Progesterone > 25 nmol/L (> 8 ng/mL): Suggests viable pregnancy (95% PPV for viable intrauterine pregnancy). Does NOT exclude ectopic.
     • Progesterone less than 5 nmol/L (less than 1.6 ng/mL): Non-viable pregnancy (failing intrauterine or ectopic). Cannot distinguish between the two.
     • Progesterone 5-25 nmol/L: Indeterminate - requires serial hCG and ultrasound follow-up.
   • Limited Use: Serial hCG is more informative. Progesterone is sometimes used as an adjunct in pregnancy of unknown location. [35]

3. Full Blood Count (FBC):

   • Haemoglobin: Acute blood loss may not be reflected immediately due to haemoconcentration. A falling Hb on serial measurements indicates ongoing bleeding.
   • White Cell Count: May be elevated due to stress response; very high WCC suggests infection (PID).

4. Group and Save / Crossmatch:

   • Group and Save: Mandatory in all suspected ectopic pregnancies.
   • Crossmatch: Request 2-4 units if patient is haemodynamically unstable or high suspicion of rupture.
   • Rhesus Status: Identify Rhesus-negative women for Anti-D immunoglobulin administration.

5. Coagulation Screen:

   • Indicated if massive haemorrhage or planned surgery. Check PT/INR, APTT, fibrinogen.

Imaging

1. Transvaginal Ultrasound Scan (TVUSS):

   • First-Line Investigation for suspected ectopic pregnancy. Superior to transabdominal ultrasound for visualizing early pregnancy and adnexal structures.

   • Diagnostic Ultrasound Features of Ectopic Pregnancy:

     • Adnexal Mass (60-95% of cases):

       • "Blob Sign": Inhomogeneous solid adnexal mass (most common finding). Non-specific - may represent ectopic pregnancy, corpus luteum, or other adnexal pathology.
       • "Bagel Sign" / "Tubal Ring Sign": Hyperechoic ring (trophoblastic tissue) surrounding an anechoic center (gestational sac). Sensitivity 50-68%, Specificity 95-100%. Presence of this sign is highly suggestive of ectopic.
       • Ectopic Gestational Sac: Extrauterine sac with or without yolk sac. Yolk sac identification has 100% specificity for ectopic pregnancy.
       • Ectopic Cardiac Activity: Visualization of fetal heartbeat outside the uterus. Pathognomonic for ectopic pregnancy (100% specific). Seen in only 10-20% of cases.

     • Empty Uterus:

       • Absence of intrauterine gestational sac when hCG > 1500-2000 IU/L is suspicious for ectopic.
       • Beware pseudogestational sac: Intrauterine fluid collection (decidual cast) seen in 10-20% of ectopic pregnancies, mimicking early gestational sac. Differentiate by:
         • True sac: Eccentric position, double decidual sign.
         • Pseudosac: Central position, single layer, no yolk sac.

     • Free Fluid:

       • Haemoperitoneum: Echogenic or complex free fluid in Pouch of Douglas, Morrison's Pouch, or perihepatic spaces.
       • Small volume may be physiological (corpus luteum rupture).
       • Large volume (> 500ml) or echogenic fluid suggests rupture.

   • Pregnancy of Unknown Location (PUL):

     • Positive pregnancy test + empty uterus + no adnexal mass on TVUSS.
     • Represents 10-30% of women scanned for suspected ectopic.
     • Differential: Very early intrauterine pregnancy, complete miscarriage, early ectopic pregnancy (pre-visualization).
     • Management: Serial hCG monitoring to guide further imaging and management. [36,37]

2. Transabdominal Ultrasound:

   • Less sensitive than TVUSS for early pregnancy but useful if TVUSS not tolerated or available.
   • Better visualization of interstitial/cornual pregnancy and upper abdominal free fluid.

3. Doppler Ultrasound:

   • Color Doppler can identify "ring of fire"

• high-velocity, low-impedance flow around ectopic gestational sac (trophoblastic vascularity).
  • Sensitivity 54-87%, Specificity 83-94%. Useful adjunct but not diagnostic alone. [38]

Invasive Investigations

1. Diagnostic Laparoscopy:

   • Gold Standard for definitive diagnosis if non-invasive tests are inconclusive and clinical suspicion remains high.
   • Indications:
     • Pregnancy of unknown location with rising or plateauing hCG and no intrauterine pregnancy on repeat scan.
     • Acute abdomen with suspected rupture where imaging is equivocal.
   • Findings:
     • Direct visualization of ectopic pregnancy (tubal mass, haematosalpinx).
     • Haemoperitoneum (blood in peritoneal cavity).
     • Can proceed to therapeutic intervention (salpingostomy/salpingectomy) in the same procedure.
   • Limitations: Invasive, requires general anaesthesia. May miss very early or already-resolved ectopic pregnancies. [39]

2. Uterine Curettage with Histology:

   • Rarely used. May be considered in pregnancy of unknown location with falling hCG to confirm intrauterine miscarriage (presence of chorionic villi).
   • Floatation Test: Products of conception from ectopic pregnancy (decidual cast) will sink in water; intrauterine chorionic villi float. Low sensitivity.
   • Arias-Stella Reaction: Histological finding of hypersecretory endometrial glands in response to progesterone stimulation. Indicates pregnancy but does NOT distinguish intrauterine from ectopic.

---

7. Management

Management depends on clinical stability, patient preference, pregnancy location, hCG level, and presence of rupture. The goal is to resolve the ectopic pregnancy while minimizing morbidity and preserving future fertility where possible.

Initial Resuscitation (Ruptured Ectopic / Haemodynamic Instability)

Immediate Actions (ABCDE Approach):

1. Airway and Breathing: Ensure patent airway; administer high-flow oxygen (15L via non-rebreather mask).
2. Circulation:
   • Establish two large-bore IV cannulae (14-16G).
   • Fluid Resuscitation: Crystalloid (Hartmann's or 0.9% saline) 500-1000ml bolus. Aim for permissive hypotension (SBP 80-90mmHg) to avoid dislodging clot prior to surgery.
   • Blood Products: Activate major haemorrhage protocol if massive bleeding. Crossmatch emergency O-negative blood if group-specific unavailable.
   • Tranexamic Acid: Consider 1g IV over 10 minutes (off-label use; evidence from trauma literature).
3. Monitoring: Continuous ECG, pulse oximetry, automated BP monitoring, urinary catheter (monitor urine output).
4. Urgent Bloods: FBC, Group and Save/Crossmatch, Coagulation screen, serum hCG.
5. Urgent Senior Review: Inform senior gynaecologist and anaesthetist immediately.
6. Emergency Surgery: Proceed to emergency laparoscopy or laparotomy without delay. Do NOT wait for hCG results or detailed imaging if patient is unstable. [1,40]

Management Algorithm

          CONFIRMED ECTOPIC PREGNANCY
                     ↓
         HAEMODYNAMICALLY STABLE?
      ┌──────────────┴──────────────┐
     NO                            YES
 (Ruptured/Shocked)                 ↓
      ↓                  MEETS EXPECTANT/MEDICAL CRITERIA?
 EMERGENCY SURGERY        ┌─────────┴─────────┐
 (Laparoscopy/Laparotomy) NO                  YES
      ↓                   ↓                    ↓
  Salpingectomy    SURGICAL MGMT     EXPECTANT or MEDICAL
      ↓            (Laparoscopy)            ↓
  Give Anti-D           ↓            Expectant: Falling hCGless than 1000
  (if RhD negative)  Salpingectomy   Medical: MTX if hCGless than 1500-5000
                     or Salpingotomy       ↓
                          ↓            Monitor hCG
                     Give Anti-D      If rising/plateau → Surgery

1. Expectant Management

Rationale: Many early ectopic pregnancies resolve spontaneously through tubal abortion or resorption without intervention. Expectant management avoids medication side effects and surgery.

Criteria (ALL must be met):

• Clinically stable with minimal or no pain.
• hCG less than 1000 IU/L (some centres use less than 1500 IU/L).
• Falling hCG trend (documented decline on serial measurements, or initial low level with high probability of spontaneous resolution).
• Ectopic mass less than 35mm on ultrasound.
• No fetal cardiac activity on ultrasound.
• No significant free fluid (haemoperitoneum) on ultrasound.
• Patient able to attend for close follow-up.
• Patient lives within reasonable distance of emergency services. [41]

Protocol:

• Serial hCG monitoring: Measure hCG every 48-72 hours initially, then weekly until negative (less than 5 IU/L).
• Expected decline: hCG should fall by ≥50% week-on-week.
• Repeat TVUSS if hCG plateau or rise, or if symptoms worsen.
• Patient Safety Advice:
  • Provide written information on red flag symptoms (severe pain, shoulder tip pain, syncope, heavy bleeding).
  • Ensure 24/7 access to emergency care.
  • Advise to avoid strenuous activity, sexual intercourse.

Success Rate: 70-80% if criteria met. Failure (requiring intervention) in 20-30%. [42]

Follow-Up: hCG monitoring continues until negative (typically 4-8 weeks). Total duration depends on initial hCG level.

2. Medical Management (Methotrexate)

Mechanism: Methotrexate is a folic acid antagonist that inhibits dihydrofolate reductase, preventing DNA synthesis and rapidly dividing trophoblastic tissue.

Criteria for Single-Dose Intramuscular (IM) Methotrexate (ALL must be met):

• Clinically stable with minimal or mild pain.
• hCG less than 1500 IU/L (NICE 2019) or less than 5000 IU/L (ACOG, RCOG - context-dependent). Lower hCG increases success rate.
• No fetal cardiac activity on ultrasound.
• Ectopic mass less than 35-40mm (ideally less than 35mm).
• No significant haemoperitoneum.
• Confirmed or highly suspected ectopic (not for pregnancy of unknown location unless intrauterine pregnancy excluded).
• Patient able to attend for close follow-up.
• No contraindications to methotrexate (see below). [1,4,43]

Absolute Contraindications:

• Breastfeeding (methotrexate excreted in breast milk).
• Immunodeficiency.
• Significant hepatic or renal impairment (eGFR less than 50 ml/min).
• Active pulmonary disease.
• Blood dyscrasias (thrombocytopaenia, anaemia, leukopenia).
• Known sensitivity to methotrexate.
• Peptic ulcer disease (active).

Relative Contraindications:

• Ectopic mass > 35-40mm.
• hCG > 5000 IU/L (reduced success rate, higher failure).
• Fetal cardiac activity present (higher failure rate, ethical considerations).
• Inability to comply with follow-up.

Dosing Protocol - Single-Dose Regimen:

• Dose: 50 mg/m² body surface area, administered intramuscularly (IM) in a single injection.
• Body Surface Area (BSA) Calculation: BSA (m²) = √[(Height (cm) × Weight (kg)) / 3600]
  • "Example: Woman 165cm, 70kg → BSA = 1.77 m² → Methotrexate dose = 88mg."

Follow-Up Protocol:

• Day 0: Administer methotrexate. Measure baseline hCG (serum β-hCG on day of administration).
• Day 4: Measure hCG (expect initial rise or plateau - NOT a treatment failure).
• Day 7: Measure hCG.
  • "Success Criteria: hCG decline ≥15% from Day 4 to Day 7."
  • "If hCG declines ≥15%: Continue weekly hCG monitoring until negative (less than 5 IU/L)."
  • "If hCG declines less than 15% (plateau or rise): Treatment failure. Options include second dose methotrexate or surgery."
• Weekly hCG until negative (typically 2-6 weeks, average 4 weeks). [44]

Multi-Dose Regimen (used in some centres, higher success but more side effects):

• Day 1, 3, 5, 7: Methotrexate 1 mg/kg IM.
• Day 2, 4, 6, 8: Folinic acid (leucovorin) 0.1 mg/kg IM (to reduce toxicity).
• Monitor hCG on Day 1, 3, 5, 7. Stop when hCG declines ≥15% from previous measurement.
• Higher success rate (90-95%) but greater side effects and complexity. [45]

Success Rates:

• Single-Dose: 80-90% overall; > 90% if hCG less than 1000 IU/L; 70-85% if hCG 1000-5000 IU/L.
• Failure Predictors: Higher hCG, larger mass, fetal cardiac activity, non-tubal ectopic (interstitial, cervical).

Side Effects:

• Common: Abdominal pain (60-70%) - expected as ectopic resolves (tubal abortion). Distinguish from rupture (severe pain, haemodynamic instability).
• GI: Nausea, vomiting, diarrhoea, stomatitis.
• Systemic: Fatigue, dizziness.
• Serious (rare with single dose): Hepatotoxicity, bone marrow suppression, pneumonitis.

Patient Counselling:

• Avoid Folate Supplements: Stop folic acid during treatment (antagonizes methotrexate).
• Avoid Pregnancy: Use reliable contraception for 3 months post-treatment (methotrexate is teratogenic). Recommended to use barrier methods or progestogen-only contraception; avoid COCP if high thrombotic risk.
• Avoid NSAIDs, Alcohol: May increase methotrexate toxicity.
• Avoid Excessive Sun Exposure: Photosensitivity.
• Avoid Sexual Intercourse, Strenuous Activity: Until ectopic resolved (risk of rupture).
• Report Red Flags: Severe abdominal pain, shoulder tip pain, syncope, heavy bleeding → attend emergency department immediately.

Anti-D Administration: Recommended for RhD-negative women (methotrexate may cause fetomaternal haemorrhage). Dose: 250 IU IM within 72 hours of methotrexate. [46]

3. Surgical Management

Indications:

• Absolute:
  • Haemodynamic instability / Ruptured ectopic.
  • Failed medical management (rising hCG post-methotrexate).
  • Contraindication to or ineligibility for medical management.
• Relative:
  • Patient preference for definitive treatment.
  • High hCG (> 5000 IU/L) or large mass (> 40mm) where medical failure risk is high.
  • Fetal cardiac activity present.
  • Inability to comply with medical management follow-up.

Surgical Approach:

Laparoscopy (Preferred):

• Advantages: Minimally invasive, shorter hospital stay (often day-case), less post-operative pain, faster recovery, better cosmetic outcome, lower adhesion formation.
• Standard of Care for haemodynamically stable patients.
• Technique: 3-4 port laparoscopy under general anaesthesia. Identify ectopic pregnancy, control bleeding, perform salpingectomy or salpingotomy.

Laparotomy:

• Indications:
  • Haemodynamic instability with massive haemoperitoneum (faster access, less reliant on gas insufflation).
  • Extensive adhesions preventing safe laparoscopy.
  • Lack of laparoscopic expertise or equipment.
• Technique: Pfannenstiel or midline incision depending on urgency and clinical scenario.

Surgical Procedures:

1. Salpingectomy (Removal of Fallopian Tube):

• Gold Standard and most common procedure.
• Indications:
  • Ruptured ectopic.
  • Extensive tubal damage.
  • Contralateral tube is healthy.
  • Patient has completed family or does not wish fertility-sparing surgery.
  • Recurrent ectopic in same tube.
• Technique: Mesosalpinx is coagulated and divided, tube is excised at cornual junction (leaving small stump). Haemostasis secured.
• Advantages:
  • Definitive treatment - no risk of persistent trophoblast.
  • Lower re-intervention rate.
  • Removes damaged tube (reduces future ectopic risk in that tube).
• Future Fertility: Subsequent intrauterine pregnancy rate 60-70%. Fertility outcomes similar to salpingotomy if contralateral tube is normal. [47,48]

2. Salpingotomy (Incision and Evacuation, Tube Preserved):

• Fertility-Sparing Procedure.
• Indications:
  • Unruptured ectopic.
  • Contralateral tube absent or damaged (only remaining functional tube).
  • Patient desires fertility preservation and meets criteria.
• Technique: Linear incision over ectopic mass on anti-mesenteric border of tube. Trophoblastic tissue evacuated with forceps and irrigation. Tubal incision left open to heal by secondary intention (or rarely sutured).
• Advantages: Preserves tubal anatomy; may improve fertility if only one tube present.
• Disadvantages:
  • "Persistent Trophoblast: Retained trophoblastic tissue continues growing in 5-20% of cases (higher risk if hCG > 3000 IU/L). Requires weekly hCG monitoring post-operatively until negative."
  • "Recurrent Ectopic: Higher rate (10-15%) of subsequent ectopic in same tube compared to contralateral tube after salpingectomy."
  • "Higher Re-intervention Rate: May require methotrexate or repeat surgery for persistent trophoblast."
• Post-Operative Management: Weekly serum hCG until negative. Rising or plateauing hCG indicates persistent trophoblast (treat with methotrexate or salpingectomy). [47,48]

Special Situations:

Cornual/Interstitial Ectopic:

• High-Risk due to late rupture (10-16 weeks) and massive haemorrhage (maternal mortality 2-2.5%).
• Surgical Options:
  • "Cornual resection: Excision of cornual ectopic with wedge resection of myometrium. Risk of uterine rupture in future pregnancy - recommend caesarean section."
  • "Medical Management: Methotrexate (systemic or local ultrasound-guided injection) - success rate lower (70-80%) than for tubal ectopic."
  • "Laparoscopic vs Laparotomy: Laparoscopic cornual resection feasible if stable; laparotomy preferred if ruptured or extensive bleeding. [6,49]"

Caesarean Scar Ectopic:

• High-Risk due to risk of uterine rupture, massive haemorrhage, placenta accreta in future pregnancies.
• Management Options:
  • "Medical: Methotrexate (systemic or local injection)."
  • "Surgical: Uterine curettage with or without hysteroscopy (risk of haemorrhage), laparoscopic/laparotomy wedge resection."
  • "Combined: Uterine artery embolization followed by curettage."
  • "Conservative: Expectant management if hCG declining and no symptoms."
• Managed in specialist centres. [8,50]

Cervical Ectopic:

• High-Risk of massive haemorrhage during surgical evacuation.
• Medical Management Preferred: Methotrexate (systemic or local injection under ultrasound guidance).
• Surgical: Uterine artery embolization prior to curettage to reduce bleeding. Hysterectomy may be required for uncontrolled haemorrhage.

Abdominal Ectopic:

• Rare. Laparotomy usually required. Placenta may be left in situ if removal risks massive haemorrhage (e.g., bowel/vascular attachment). Methotrexate may be administered post-operatively to accelerate placental resorption. [51]

Anti-D Immunoglobulin Administration:

• All RhD-negative women undergoing surgical management should receive Anti-D immunoglobulin.
• Dose: 250 IU IM if gestation less than 20 weeks (ectopic pregnancies are always less than 20 weeks).
• Timing: Within 72 hours of surgery (ideally intra-operatively or immediately post-operatively). [46]

4. Pregnancy of Unknown Location (PUL) Management

Definition: Positive pregnancy test + empty uterus on TVUSS + no visible adnexal mass.

Differential:

• Very early intrauterine pregnancy (hCG below discriminatory zone).
• Early ectopic pregnancy (pre-visualization on ultrasound).
• Recent complete miscarriage (hCG falling).

Management Protocol:

1. Baseline serum hCG + serum progesterone (optional).
2. Repeat serum hCG at 48 hours:
   • Rise ≥66%: Likely viable intrauterine pregnancy → Repeat TVUSS in 7-14 days (when hCG > 1500 IU/L).
   • Fall ≥50%: Likely complete miscarriage → Monitor hCG to negative.
   • Suboptimal rise or plateau (change -50% to +66%): Possible ectopic or failing intrauterine pregnancy → Repeat TVUSS. Consider methotrexate vs expectant vs laparoscopy based on clinical picture and hCG trend.
3. Laparoscopy: If hCG rising/plateauing and repeat TVUSS remains non-diagnostic, or clinical suspicion of ectopic is high.

Follow-Up: Weekly hCG monitoring until negative if expectant management. [33,52]

---

8. Complications

Acute Complications

1. Tubal Rupture:

   • Occurs in 15-30% of ectopic pregnancies.
   • Presentation: Sudden-onset severe abdominal pain, shoulder tip pain, syncope, haemodynamic instability.
   • Management: Emergency surgery.

2. Haemorrhagic Shock:

   • Blood loss can exceed 2-3 litres in cornual rupture.
   • Management: Aggressive resuscitation, blood transfusion, emergency surgery.
   • Maternal Mortality: 0.1-0.5 per 1000 ectopic pregnancies in developed countries; higher in low-resource settings. [2]

3. Persistent Trophoblast (Post-Salpingotomy):

   • Retained trophoblastic tissue continues growing.
   • Incidence: 5-20% after salpingotomy (vs less than 1% after salpingectomy).
   • Diagnosis: Rising or plateauing hCG post-operatively.
   • Management: Methotrexate or repeat surgery (salpingectomy). [47]

4. Treatment Failure (Medical Management):

   • Incidence: 10-20% for single-dose methotrexate.
   • Presentation: Rising hCG, worsening symptoms.
   • Management: Second dose methotrexate or surgery.

Long-Term Complications

1. Recurrent Ectopic Pregnancy:

   • Risk: 10-15% after one ectopic; 25-30% after two ectopic pregnancies.
   • Prevention: Early scan in future pregnancies (6-7 weeks gestation) to confirm intrauterine location. [15]

2. Infertility:

   • Subsequent Intrauterine Pregnancy Rates:
     • 60-70% after salpingectomy (one tube).
     • 50-60% after salpingotomy.
     • 30-40% if bilateral tubal damage.
   • Factors: Age, contralateral tubal patency, presence of other risk factors (PID, endometriosis).
   • Assisted Reproductive Technology: IVF is an option if tubes are damaged or absent. [48]

3. Psychological Impact:

   • Grief and loss associated with pregnancy loss.
   • Anxiety regarding future fertility and recurrence.
   • Support: Counselling, support groups (e.g., Ectopic Pregnancy Trust, Miscarriage Association).

---

9. Prognosis and Outcomes

Survival and Maternal Outcomes

• Maternal Mortality: 0.1-0.5 per 1000 ectopic pregnancies in high-resource settings. Leading cause of first-trimester maternal death. Mortality higher in low-resource settings (2-3 per 1000). [2]
• Morbidity: Mostly related to haemorrhage and surgical complications. Long-term morbidity is primarily related to fertility outcomes.

Fertility Outcomes

• Subsequent Intrauterine Pregnancy:

  • "Overall: 60-70% of women achieve subsequent intrauterine pregnancy after ectopic."
  • "After Salpingectomy: 60-70% (similar to salpingotomy if contralateral tube normal)."
  • "After Salpingotomy: 50-60% (higher recurrent ectopic risk)."
  • "After Medical Management: 60-80% (tube preserved, but underlying tubal pathology remains). [48]"

• Recurrent Ectopic: 10-15% after one ectopic; 25-30% after two ectopic pregnancies. [15]

• Need for Assisted Conception: 20-30% of women with history of ectopic pregnancy will require ART (IVF) to achieve pregnancy.

Factors Affecting Prognosis

• Age: Fertility declines with age; older women have lower subsequent pregnancy rates.
• Tubal Pathology: Bilateral tubal damage significantly reduces natural conception rates.
• Prior Fertility: Women with previous successful pregnancies have better outcomes.
• Early Diagnosis: Reduces rupture risk and allows less invasive management options.

---

10. Prevention and Future Pregnancy

Primary Prevention

1. STI Prevention: Barrier contraception (condoms) reduces PID risk. Routine Chlamydia screening in sexually active young women.
2. Prompt PID Treatment: Early antibiotic treatment of PID reduces tubal damage.
3. Smoking Cessation: Reduces ectopic pregnancy risk.

Secondary Prevention (Reducing Recurrence)

1. Early Pregnancy Scan: All women with history of ectopic pregnancy should have early viability scan at 6-7 weeks gestation in future pregnancies to confirm intrauterine location.
2. Low Threshold for Investigation: Any pain or bleeding in early pregnancy warrants urgent assessment.
3. Contraceptive Counselling: IUCD may not be optimal choice in women with high ectopic risk.

Preconception Counselling

• Recurrence risk 10-15%.
• 60-70% chance of successful intrauterine pregnancy.
• Early presentation and scan in future pregnancy.
• Awareness of symptoms.
• Consider ART (IVF) if bilateral tubal damage or recurrent ectopic.

---

11. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. Mol et al. (2014) - ESEP Study (Lancet):

• Design: Multi-centre RCT comparing salpingotomy vs salpingectomy.
• Findings: Similar subsequent intrauterine pregnancy rates (60% salpingotomy vs 56% salpingectomy, p=0.47). Higher persistent trophoblast rate (7% vs 0%) and repeat intervention rate (15% vs 3%) with salpingotomy.
• Conclusion: Salpingectomy is the preferred procedure unless only one tube remains functional. [47]

2. Barnhart et al. (2009) - Methotrexate Multi-Dose vs Single-Dose (Obstet Gynecol):

• Design: Meta-analysis of 26 studies (1,327 women).
• Findings: Multi-dose methotrexate more effective than single-dose (93% vs 88% success, p=0.01) but higher side effects and complexity.
• Conclusion: Single-dose methotrexate is first-line for eligible patients; multi-dose reserved for failures or high-risk cases. [44]

3. Elson et al. (2004) - Expectant Management (Hum Reprod):

• Findings: Expectant management successful in 69% of women with declining hCG less than 1000 IU/L.
• Conclusion: Expectant management is safe and effective in carefully selected low-risk patients. [41]

4. Kirk et al. (2014) - Discriminatory hCG Zone (Fertil Steril):

• Findings: Using discriminatory zone of 1500 IU/L, sensitivity 93%, specificity 100% for detecting intrauterine pregnancy on TVUSS.
• Conclusion: Discriminatory zone of 1500-2000 IU/L is appropriate for clinical use. [34]

5. Chong et al. (2024) - Nature Reviews Disease Primers:

• Comprehensive Review: Pathophysiology, diagnosis, management, and future directions in ectopic pregnancy research.
• Key Points: Molecular mechanisms (PROKR1, integrins), novel biomarkers under investigation, emphasis on patient-centered care and psychological support. [31]

---

12. Patient and Layperson Explanation

What is an Ectopic Pregnancy?

In a normal pregnancy, the fertilized egg travels down the Fallopian tube (a thin tube connecting the ovary to the womb) and implants in the lining of the womb, where it grows into a baby. In an ectopic pregnancy, the fertilized egg gets stuck in the tube and starts growing there instead of in the womb.

Why is it Dangerous?

The Fallopian tube is a narrow pipe, much thinner than the womb. It cannot stretch to accommodate a growing pregnancy. As the pregnancy grows, it will eventually cause the tube to burst (rupture), leading to serious internal bleeding. This is a medical emergency and can be life-threatening if not treated urgently.

Can the Baby Survive?

Unfortunately, no. An ectopic pregnancy cannot develop into a healthy baby. The embryo cannot survive outside the womb, and there is no way to move or transplant it to the correct location. The pregnancy must be treated to prevent serious complications.

What are the Symptoms?

Common symptoms include:

• Tummy pain, usually on one side
• Vaginal bleeding (often lighter than a period)
• Missed period (though some women mistake early bleeding for a period)
• Shoulder tip pain (pain at the tip of your shoulder)
• Feeling faint, dizzy, or collapsing

If you experience severe tummy pain, shoulder tip pain, heavy bleeding, or feel faint, call 999 or go to A&E immediately.

How is it Diagnosed?

Your doctor will:

1. Do a pregnancy test (urine or blood).
2. Perform an internal ultrasound scan to look for the pregnancy.
3. Take blood tests to measure pregnancy hormone levels (hCG).

Sometimes, the diagnosis isn't clear immediately, and you may need repeat scans and blood tests over a few days.

How is it Treated?

There are three main treatment options:

1. Watchful Waiting (Expectant Management):

   • If the pregnancy is very early and hormone levels are falling, it may resolve on its own without treatment.
   • You'll need regular blood tests to make sure hormone levels are dropping.

2. Medication (Methotrexate Injection):

   • A single injection is given into your muscle (usually buttock or thigh) to stop the pregnancy growing.
   • You'll need regular blood tests for several weeks to ensure it's working.
   • You must avoid getting pregnant for 3 months after the injection as the medication can harm a developing baby.
   • You should avoid alcohol, folic acid supplements, and strenuous activity during treatment.

3. Surgery (Keyhole Operation):

   • Surgery is needed if you're unwell, in pain, or the other treatments aren't suitable.
   • Usually performed as keyhole surgery under general anaesthetic.
   • The surgeon will remove the ectopic pregnancy. Often, the affected Fallopian tube is also removed.

Will I be Able to Have Children in the Future?

Yes, most women can have successful pregnancies after an ectopic pregnancy. Even with only one Fallopian tube, your chances of getting pregnant naturally are good (about 60-70%). The remaining tube can "pick up" eggs from both ovaries.

However, there is a small risk (about 1 in 10) that an ectopic pregnancy could happen again. If you become pregnant in the future, it's important to have an early scan (around 6-7 weeks) to confirm the pregnancy is in the right place.

Where Can I Get Support?

• Ectopic Pregnancy Trust: www.ectopic.org.uk - UK charity providing information and support.
• Miscarriage Association: Offers emotional support for pregnancy loss.
• Your GP or Early Pregnancy Unit: Can refer you to counselling services if needed.

Losing a pregnancy is emotionally difficult. It's normal to feel sad, anxious, or worried about future pregnancies. Don't hesitate to ask for support.

---

13. Examination Focus

MRCOG / FRANZCOG High-Yield Topics

1. Diagnosis of Ectopic Pregnancy:

• Discriminatory Zone: hCG level (1500-2000 IU/L) above which intrauterine gestational sac should be visible on TVUSS. Empty uterus with hCG above this level is highly suspicious for ectopic.
• Serial hCG Interpretation:
  • "Viable intrauterine: Rises ≥66% in 48 hours."
  • "Ectopic/failing: Suboptimal rise (less than 53%) or plateau."
  • "Miscarriage: Falls ≥50% in 48 hours."
• Ultrasound Signs:
  • "Tubal Ring Sign" / "Bagel Sign": Hyperechoic ring around ectopic sac.
  • "Ectopic cardiac activity: Pathognomonic (100% specific)."
  • "Pseudogestational sac: Mimics early intrauterine pregnancy; central location, no yolk sac."

2. Management of Ectopic Pregnancy:

• Methotrexate Criteria (Single-Dose):
  • hCG less than 1500 IU/L (NICE) or less than 5000 IU/L (ACOG, context-dependent).
  • No fetal cardiac activity.
  • Mass less than 35mm.
  • Clinically stable.
  • Able to follow up.
• Methotrexate Protocol:
  • "Dose: 50 mg/m² IM."
  • "Follow-up: hCG on Day 0, Day 4, Day 7. Success = ≥15% decline Day 4 to Day 7."
  • "Patient advice: Avoid pregnancy for 3 months, avoid folic acid, NSAIDs, alcohol, strenuous activity."
• Salpingectomy vs Salpingotomy:
  • "Salpingectomy: Standard. Lower re-intervention, no persistent trophoblast risk. Future fertility similar to salpingotomy if contralateral tube normal."
  • "Salpingotomy: Only if contralateral tube absent/damaged. Risk: persistent trophoblast 5-20%, recurrent ectopic 10-15%."

3. Shoulder Tip Pain:

• Mechanism: Referred pain (C3-C5 dermatome) from phrenic nerve irritation by blood beneath diaphragm.
• Significance: Highly specific for haemoperitoneum. Mandates urgent surgical evaluation.

4. Heterotopic Pregnancy:

• Definition: Simultaneous intrauterine and ectopic pregnancy.
• Incidence: Spontaneous 1:30,000; IVF 1:100-1:500.
• Clinical Significance: Visualization of intrauterine pregnancy does NOT exclude ectopic in IVF patients.

5. Anti-D Immunoglobulin:

• Indications: All RhD-negative women with ectopic pregnancy undergoing:
  • "Surgery: YES (mandatory)."
  • "Medical Management (Methotrexate): YES (recommended)."
  • "Expectant Management: Usually not required (but some guidelines recommend)."
• Dose: 250 IU IM if less than 20 weeks gestation.
• Timing: Within 72 hours of intervention.

6. Pregnancy of Unknown Location (PUL):

• Definition: Positive pregnancy test + empty uterus + no adnexal mass on TVUSS.
• Management: Serial hCG (48 hours).
  • "Rise ≥66%: Repeat scan (likely intrauterine)."
  • "Fall ≥50%: Likely miscarriage, monitor to negative."
  • "Plateau: Possible ectopic, repeat scan or consider laparoscopy."

7. Cornual/Interstitial Ectopic:

• Incidence: 2-4% of ectopic pregnancies.
• Risk: Late rupture (10-16 weeks), catastrophic haemorrhage, maternal mortality 2-2.5%.
• Management: Surgical (cornual resection) or medical (methotrexate - lower success than tubal). Future pregnancies require caesarean section if cornual resection performed.

8. Arias-Stella Reaction:

• Definition: Histological finding in endometrium showing hypersecretory glands and cellular atypia in response to progesterone.
• Significance: Indicates pregnancy (intrauterine or ectopic) but does NOT localize it. Can mimic endometrial carcinoma histologically.

---

Common Viva Questions and Model Answers

Q1: A 28-year-old woman presents with 7 weeks amenorrhoea, right iliac fossa pain, and minimal vaginal bleeding. Pregnancy test is positive. TVUSS shows an empty uterus and a 2cm right adnexal mass. Serum hCG is 1200 IU/L. How would you manage her?

Model Answer: "This presentation is suspicious for ectopic pregnancy. The patient is clinically stable. I would:

1. Confirm diagnosis: Empty uterus with hCG > 1000-1200 is concerning for ectopic, though hCG is just below the discriminatory zone (1500 IU/L). The adnexal mass supports ectopic.
2. Management options: Given hCG less than 1500 IU/L, stable patient, and mass less than 35mm, she is a candidate for expectant or medical management.
   • Expectant: If hCG is falling on repeat measurement in 48 hours.
   • Medical (Methotrexate): If hCG rising or plateau. Single-dose IM methotrexate 50mg/m². Follow-up hCG Day 4 and Day 7. Success defined as ≥15% decline Day 4-7.
   • Surgical: If patient prefers, or if medical contraindications.
3. Counselling: Explain diagnosis, management options, risks/benefits, need for close follow-up. Safety-netting advice (red flags: severe pain, shoulder tip pain, syncope → attend A&E).
4. Anti-D: If RhD-negative, administer 250 IU IM if proceeding with methotrexate or surgery."

Q2: What are the contraindications to methotrexate?

Model Answer: "Absolute contraindications:

• Breastfeeding
• Immunodeficiency
• Hepatic or renal impairment (eGFR less than 50)
• Active pulmonary disease
• Blood dyscrasias
• Methotrexate hypersensitivity
• Active peptic ulcer disease

Relative contraindications:

• High hCG (> 5000 IU/L) - reduced success rate
• Large ectopic mass (> 35-40mm)
• Fetal cardiac activity present
• Inability to comply with follow-up"

Q3: What is the discriminatory zone, and what are its limitations?

Model Answer: "The discriminatory zone is the serum hCG level above which an intrauterine gestational sac should be visible on transvaginal ultrasound in a normal singleton pregnancy. It is typically 1500-2000 IU/L, though some centres use up to 3000 IU/L to reduce false positives.

Limitations:

1. Multiple Pregnancy: Twins may have higher hCG but smaller sacs, potentially not visible at 1500 IU/L.
2. Ultrasound Quality: Operator-dependent; poor-quality scans may miss small intrauterine sacs.
3. Individual Variation: Some normal pregnancies have lower hCG at time of sac visualization.
4. Ectopic vs Early IUP: An empty uterus with hCG just above the discriminatory zone could represent either ectopic or very early intrauterine pregnancy. Serial hCG and repeat scanning are essential to avoid misdiagnosis."

Q4: What is the role of serum progesterone in diagnosing ectopic pregnancy?

Model Answer: "Serum progesterone is a single measurement that can help assess pregnancy viability but does NOT distinguish between intrauterine and ectopic pregnancy.

Interpretation:

• Progesterone > 25 nmol/L: Suggests viable pregnancy (likely intrauterine, but ectopic NOT excluded).
• Progesterone less than 5 nmol/L: Non-viable pregnancy (failing intrauterine or ectopic - cannot distinguish).
• Progesterone 5-25 nmol/L: Indeterminate - requires further investigation.

Role: Adjunct in pregnancy of unknown location to triage patients. However, serial hCG and ultrasound are more informative for diagnosis and management decisions."

Q5: Why is salpingectomy now preferred over salpingotomy?

Model Answer: "Salpingectomy is now the preferred surgical treatment for ectopic pregnancy based on evidence from the ESEP Study (Mol et al., Lancet 2014).

Key findings:

• Similar future fertility: Subsequent intrauterine pregnancy rates were similar (60% salpingotomy vs 56% salpingectomy, p=0.47), provided the contralateral tube is healthy.
• Lower complications with salpingectomy:
  • No risk of persistent trophoblast (7% risk with salpingotomy vs 0% with salpingectomy).
  • Lower re-intervention rate (3% vs 15%).
  • Lower recurrent ectopic in treated tube.

Salpingotomy indications: Reserved for cases where the contralateral tube is absent or severely damaged, as preserving the only functional tube may improve fertility outcomes. However, patients must be counselled about persistent trophoblast risk and need for weekly hCG monitoring post-operatively."

---

14. Future Directions and Research

Novel Biomarkers:

• Investigating activin A, inhibin A, VEGF, and pregnancy-associated plasma protein-A (PAPP-A) as adjuncts to hCG for earlier and more accurate diagnosis of ectopic pregnancy. [31]

Non-Surgical Treatments:

• Alternative Medical Agents: Research into mifepristone, gefitinib (EGFR inhibitor), and other agents as alternatives to methotrexate.
• Ultrasound-Guided Injection: Local injection of methotrexate or potassium chloride directly into ectopic gestational sac under ultrasound guidance. [54]

Regenerative Medicine:

• Investigating tubal repair techniques and stem cell therapies to restore tubal function post-ectopic.

Prevention:

• Universal Chlamydia screening programs to reduce PID and subsequent tubal damage.
• Development of vaccines against Chlamydia trachomatis.

---

15. References

Primary Sources

1. National Institute for Health and Care Excellence (NICE). Ectopic pregnancy and miscarriage: diagnosis and initial management. NICE guideline [NG126]. 2019. Available at: https://www.nice.org.uk/guidance/ng126
2. Chong KY, et al. Ectopic pregnancy. Nat Rev Dis Primers. 2024;10(1):94. doi:10.1038/s41572-024-00579-x
3. Mullany K, et al. Overview of ectopic pregnancy diagnosis, management, and innovation. Womens Health (Lond). 2023;19:17455057231160349. doi:10.1177/17455057231160349
4. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy. Obstet Gynecol. 2018;131(3):e91-e103. doi:10.1097/AOG.0000000000002560
5. Brim ACS, et al. Risk factors for ectopic pregnancy occurrence: Systematic review and meta-analysis. Int J Gynaecol Obstet. 2025;168(2):415-429. doi:10.1002/ijgo.15965
6. Gaetani M, et al. Cornual Pregnancy. Gynecol Minim Invasive Ther. 2023;12(4):209-213. doi:10.4103/gmit.gmit_10_23
7. Obaid M, et al. Cornual or interstitial ectopic pregnancy? Am J Obstet Gynecol. 2024;231(4):e1-e4. doi:10.1016/j.ajog.2024.05.052
8. Society for Maternal-Fetal Medicine (SMFM). Society for Maternal-Fetal Medicine Consult Series #63: Cesarean scar ectopic pregnancy. Am J Obstet Gynecol. 2022;227(5):B2-B14. doi:10.1016/j.ajog.2022.06.024
9. Synnott D, et al. Management of tubal ectopic pregnancy in a large maternity unit; a six-year review. Eur J Obstet Gynecol Reprod Biol. 2025;306:108-113. doi:10.1016/j.ejogrb.2025.02.058
10. Dvash S, et al. Increase rate of ruptured tubal ectopic pregnancy during the COVID-19 pandemic. Eur J Obstet Gynecol Reprod Biol. 2021;259:95-99. doi:10.1016/j.ejogrb.2021.01.054
11. Dicker D, et al. Heterotopic pregnancy after IVF-ET: report of a case and a review of the literature. Hum Reprod. 1989;4(8):944-946.
12. Ku CW, et al. Abdominal heterotopic pregnancy post-IVF double embryo transfer. BMJ Case Rep. 2022;15(2):e246649. doi:10.1136/bcr-2021-246649
13. Arnold MJ, et al. Point-of-Care Ultrasonography. Am Fam Physician. 2020;101(5):275-285.
14. Jenabi E, et al. The environmental risk factors associated with ectopic pregnancy: An umbrella review. J Gynecol Obstet Hum Reprod. 2023;52(2):102532. doi:10.1016/j.jogoh.2022.102532
15. Rosen A, et al. Pregnancy outcomes following medical vs surgical treatment of tubal ectopic pregnancy: a population-based retrospective cohort study. Am J Obstet Gynecol. 2025 (online ahead of print). doi:10.1016/j.ajog.2025.07.008
16. Ng KYB, et al. Hydrosalpinx - Salpingostomy, salpingectomy or tubal occlusion. Best Pract Res Clin Obstet Gynaecol. 2019;59:41-47. doi:10.1016/j.bpobgyn.2019.01.011
17. Mastroianni L Jr. The fallopian tube and reproductive health. J Pediatr Adolesc Gynecol. 1999;12(3):127-132.
18. Nager CW, et al. Ectopic pregnancy. Clin Obstet Gynecol. 1991;34(3):403-411.
19. Hufstetler K, et al. Clinical Updates in Sexually Transmitted Infections, 2024. J Womens Health (Larchmt). 2024;33(6):706-714. doi:10.1089/jwh.2024.0367
20. (Additional reference - see citation 5 for comprehensive risk factor meta-analysis)
21. (Risk factors discussed comprehensively in references 3, 5, 14)
22. (Discussed in risk factors section - evidence from multiple sources including references 3, 5)
23. (Discussed in risk factors section - evidence from multiple sources including references 3, 5)
24. (Discussed in reference 14 - environmental risk factors umbrella review)
25. (Molecular mechanisms discussed in reference 2 - Nature Reviews primer)
26. (Discussed in reference 5 - risk factors meta-analysis)
27. (Protective factors discussed in reference 5)
28. (Normal physiology - reference 17, Mastroianni)
29. (PID pathophysiology - reference 19)
30. (Tubal rupture mechanisms - references 2, 3, 9, 10)
31. (Molecular mechanisms and future directions - reference 2, Chong et al. Nature Reviews)
32. (Pregnancy testing - reference 1, NICE guideline)
33. Po L, et al. Guideline No. 414: Management of Pregnancy of Unknown Location and Tubal and Nontubal Ectopic Pregnancies. J Obstet Gynaecol Can. 2021;43(5):614-630.e1. doi:10.1016/j.jogc.2021.01.002
34. Kirk E, et al. The diagnostic effectiveness of an initial transvaginal scan in detecting ectopic pregnancy. Hum Reprod. 2014;29(12):2464-2472. (Discriminatory zone evidence)
35. (Progesterone discussed in references 1, 4, 33)
36. (TVUSS diagnostic features - references 1, 4, 13, 33)
37. (PUL discussed in reference 33)
38. (Doppler ultrasound - adjunct evidence in ultrasound literature, referenced in guidelines 1, 4)
39. Kathopoulis N, et al. Laparoscopic cornual resection for interstitial pregnancy: Staying in the Marginal Zone. Facts Views Vis Obgyn. 2024;16(3):285-290. doi:10.52054/FVVO.16.3.032
40. (Emergency management - references 1, 4, 9, 10)
41. Elson J, et al. Expectant management of tubal ectopic pregnancy: prediction of successful outcome using decision tree analysis. Hum Reprod. 2004;19(5):1210-1217. (Expectant management evidence)
42. Solangon SA, et al. Methotrexate vs expectant management for treatment of tubal ectopic pregnancy: An individual participant data meta-analysis. Acta Obstet Gynecol Scand. 2023;102(9):1129-1139. doi:10.1111/aogs.14617
43. (Methotrexate criteria - references 1, 4, 33)
44. Barnhart KT, et al. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol. 2003;101(4):778-784. (Methotrexate dosing)
45. (Multi-dose methotrexate - reference 44)
46. (Anti-D - references 1, 4, 53)
47. Mol F, et al. Salpingotomy versus salpingectomy in women with tubal pregnancy (ESEP study): an open-label, multicentre, randomised controlled trial. Lancet. 2014;383(9927):1483-1489.
48. (Fertility outcomes - references 15, 47)
49. (Cornual ectopic management - references 6, 7, 39)
50. Birch Petersen K, et al. Cesarean scar pregnancy: a systematic review of treatment studies. Fertil Steril. 2016;105(4):958-969. doi:10.1016/j.fertnstert.2015.12.130
51. Dunphy L, et al. Abdominal ectopic pregnancy. BMJ Case Rep. 2023;16(9):e252960. doi:10.1136/bcr-2022-252960
52. (PUL management - reference 33)
53. Elson J, et al. Diagnosis and management of ectopic pregnancy: Green-top Guideline No. 21. BJOG. 2016;123(13):e15-e55. (RCOG guideline)
54. Leziak M, et al. Future Perspectives of Ectopic Pregnancy Treatment-Review of Possible Pharmacological Methods. Int J Environ Res Public Health. 2022;19(21):14230. doi:10.3390/ijerph192114230

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and local guidelines. Always consult appropriate specialists and senior colleagues. In emergencies, prioritize immediate resuscitation and definitive management.